IP Library Granted Patent US 11,577,006
Granted Patent B2
US 11,577,006 · App. 17/080,460 · Granted Feb 14, 2023

Bioimplant

Inventors: Masaaki Mawatari (Saga, JP); Masatsugu Tsukamoto (Saga, JP); Iwao Noda (Osaka, JP)
Assignees: KYOCERA CORPORATION; SAGA UNIVERSITY
A61L27/54A61L27/32A61L2300/104A61L2300/404A61L2420/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,577,006
App. No.
17/080,460
Granted
Feb 14, 2023
Kind
B2
Abstract

Provided is a bioimplant which is capable to inhibit the biofilm formation over a long period of time after an operation. The bioimplant of the present invention comprises a base material of metal, ceramic, or plastic and a thermal spraying film of a calcium phosphate-based material formed at least partially thereon and the silver concentration in the thermal-spray film is 0.05 wt % to 3.00 wt %.

Claims (9)

1. A bioimplant, comprising

a base material of the bioimplant;

a coating film comprising a calcium phosphate-based material and a silver material formed on at least a part of a surface of the base material;

wherein the calcium phosphate-based material comprises oxyapatite and hydroxyapatite, wherein the hydroxyapatite is formed from converting oxyapatite present in the coating into the hydroxyapatite by immersing the coating in deionized water, and

wherein fine crystals of the hydroxyapatite are present on a surface of the coating film, wherein a size of the fine crystals of hydroxyapatite is in a range of 0.01 μm to 2.00 μm in length, thickness or width.

2. The bioimplant according to claim 1 , wherein the silver material concentration in the coating film is in a range of 0.05 wt % to 3.00 wt %.

3. The bioimplant according to claim 1 , wherein the base material comprises a metal.

4. The bioimplant according to claim 1 , wherein the calcium phosphate-based material further comprises a compound or a mixture of two or more compounds selected from the group consisting of alpha-tricalcium phosphate, beta-tricalcium phosphate, and tetracalcium phosphate.

5. The bioimplant according to claim 1 , wherein the bioimplant has a bone contact portion, at least part of the bone contact portion is covered with the coating film.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2026
From: KYOCERA CORPORATION
To: KYOCERA MEDICAL CORPORATION
Reel/Frame 074696/0343 →
Priority Claims (1)
JP 2012-022205 · Feb 3, 2012 · national
Continuity (3)
Continuation 15405156 · Jan 12, 2017
Continuation In Part 14376183
Related Publication 20210052780A1 · Feb 25, 2021